-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharming Group Delivers Strong Preliminary 2025 Revenue Growth Of Approximately 27% YoY To $376M, Driven By RUCONEST And Joenja

Benzinga·01/08/2026 06:28:45
Listen to the news

Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the U.S. and supported by ongoing geographic expansion. Full-year 2025 operating expenses are expected to be within the previously communicated range of US$304 to US$308 million, underscoring our commitment to cost discipline. Looking ahead, we anticipate sustained revenue growth and continued advancement of our clinical pipeline in 2026. We plan to report complete fourth quarter and full year 2025 financial results on March 12, 2026.